- Home
- OMCL vs ZYME Comparison
OMCL vs ZYME Comparison
Compare OMCL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | ZYME |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | United States |
| Employees | N/A | 264 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OMCL | ZYME |
|---|---|---|
| Price | $35.07 | $24.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $51.14 | $38.90 |
| AVG Volume (30 Days) | 528.7K | ★ 633.3K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | $105,965,000.00 |
| Revenue This Year | $6.77 | $162.82 |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $876.50 | ★ N/A |
| Revenue Growth | 9.93 | ★ 38.87 |
| 52 Week Low | $22.66 | $9.03 |
| 52 Week High | $51.84 | $28.49 |
Technical Indicators
Market Signals| Indicator | OMCL | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 52.09 |
| Support Level | $33.25 | $22.23 |
| Resistance Level | $37.51 | $27.54 |
| Average True Range (ATR) | 1.44 | 1.42 |
| MACD | -0.48 | -0.04 |
| Stochastic Oscillator | 14.03 | 32.23 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.